Market Report, "Germany Pharmaceuticals & Healthcare Report Q3 2014", Published
BMI View: Germany's medicines pricing regime will continue to restrict drugmaker s' revenue streams. The AMNOG has proved to be tough, with the majority of medicine reimbursement prices lying under the average of or below the lowest of the European reference country basket. Additionally, legislators have voted to continue the 2010 implemented price freeze on reimbursed drugs until the end of 2017. However, the long term and clear nature of the measures implemented by the government is a much more...
View full press release